A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in A Tyr Pharma Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 7,500 shares of LIFE stock, worth $15,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,500
Previous 700 971.43%
Holding current value
$15,000
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.42 - $2.02 $212,639 - $302,486
149,746 Added 8.54%
1,903,346 $3.71 Million
Q4 2023

Feb 14, 2024

SELL
$1.11 - $1.51 $33,894 - $46,109
-30,536 Reduced 1.71%
1,753,600 $2.47 Million
Q3 2023

Nov 14, 2023

BUY
$1.55 - $2.23 $2.27 Million - $3.26 Million
1,464,046 Added 457.39%
1,784,136 $2.82 Million
Q2 2023

Aug 14, 2023

BUY
$1.72 - $2.57 $480,156 - $717,443
279,161 Added 682.06%
320,090 $691,000
Q1 2023

May 15, 2023

BUY
$1.88 - $2.5 $5,812 - $7,730
3,092 Added 8.17%
40,929 $85,000
Q4 2022

Feb 14, 2023

BUY
$2.02 - $2.49 $76,430 - $94,214
37,837 New
37,837 $82,000
Q1 2022

May 16, 2022

SELL
$4.75 - $7.54 $159,471 - $253,140
-33,573 Reduced 17.35%
159,921 $855,000
Q4 2021

Feb 14, 2022

SELL
$7.29 - $9.5 $50,454 - $65,749
-6,921 Reduced 3.45%
193,494 $1.45 Million
Q3 2021

Nov 15, 2021

BUY
$4.22 - $12.48 $719,687 - $2.13 Million
170,542 Added 570.89%
200,415 $1.82 Million
Q2 2021

Aug 16, 2021

BUY
$3.62 - $4.88 $59,378 - $80,046
16,403 Added 121.77%
29,873 $145,000
Q1 2021

May 17, 2021

BUY
$3.53 - $8.06 $47,549 - $108,568
13,470 New
13,470 $60,000
Q3 2020

Nov 16, 2020

SELL
$3.23 - $5.39 $38,753 - $64,669
-11,998 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$2.55 - $4.58 $16,847 - $30,260
-6,607 Reduced 35.51%
11,998 $53,000
Q1 2020

May 15, 2020

BUY
$2.17 - $7.06 $10,483 - $34,106
4,831 Added 35.07%
18,605 $52,000
Q4 2019

Feb 14, 2020

BUY
$3.03 - $4.83 $41,735 - $66,528
13,774 New
13,774 $57,000

Others Institutions Holding LIFE

About aTYR PHARMA INC


  • Ticker LIFE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,625,000
  • Market Cap $57.3M
  • Description
  • aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for ...
More about LIFE
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.